Please type a plus sign (+) Inside this box ->

NO. 6385 CEIVED

NO. 6385 CEIVED

Applete if Known TECH CENTER 1600/2900

					Complete if Known LOTT CENTER 1600	/290(
Substitute for John 1440400				Application Number	09/930,283	
				Filing Date	August 16, 2001	
				First Named Inventor	Kasid et al.	;
				Group Art Unit	1635	
				Examiner Name	Terrea C. Gibbs	
(Use as many sheets as necessary)				Attorney Docket Number	219603	
Sheet I	7	of	l			

Examiner	Doc. No.	U.S. Patent Document			Date of	Filing Date If
		Application or Patent Number	Kind Code	Name of Patentee or Applicant	Publication	Appropriate
Initials	AA	5,641,662		Debs et al.	June 24, 1997	
<u>yr</u>	AB	5,696,277	1	Hostetler et al.	Dec. 9, 1997	
	AC	5,827,703		Debs et al.	Oct. 27, 1998	
- 	AD	6,120,798		Allen et al.	Sep. 19, 2000	
- 188	AE	6,248,351	B1	Xing et al.	June 19, 2001	
						

FOREIGN PATENT DOCUMENTS							Translation	
		Fo	reign Patent Docume	nl		- 40-bi-siaa	Yes	No⊶
Examiner	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	163	140
Initials	140.	 			·			├
		 						├ ─
								├
		+					 -	₩
		├── ┤						╄
				\bot				T

OTHER - NON PATENT LITERATURE DOCUMENTS OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Include name of the author (in CAPITAL LETTERS), date page(s), volume-issue number (s), publisher,					
miner Initials	Doc. No.	(book, magazine, Journal, senal, symposium, catalog, etc.), date, page-2.	Yes	No**	
Lo	AF	GOKHALE et al., "Enhanced inhibition of Raf-1 kinase by liposomal antisense raf oligodeoxyribonucleotide in human squamous carcinoma cells," American Asso. Cancer Research, 37, Poster Section 6 #2807 (1996)			
	AG	GOKHALE et al., "Antisense raf oligodeoxyribonucleotide is protected by inposornal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for encapsulation and inhibits Raf-1 protein expression in vitro and inhibits Raf-1 prot			
\top	АН	GOKHALE et al., "Antisense raf Oligodeoxynbonucleotide is a Radiosettsiazer in the		 -	
	ΑI	LITIZINGER et al., *Fate of cationic liposomes and their complex with ongonistics and their complex with one of their complex with one of their complex with one of their complex with their complex with one of their complex with one of their complex with the		-	
	LA	MAHER et al., "Specific Hybridization Arrest of Dinydrotolate Reductase Invited in Vision Anti-sense RNA or Anti-sense Oligonucleotides," Archives of Biochemistry and Richards 253, 214-220 (1987)	_		
) LY	AK	SOLDAATENKOV et al., "Inhibition of Raf-1 Protein Kinase by Antisense Phosphorothioate Oligodeoxyribonucleotide Is Associated with Sensitization of Human Laryngeal Squamous Carcinoma Cells to Gamma Radiation," Cancer J. Sci. Am., 3, 13-20 (1997)			

	- A A A	Date Considered	2/10/24
Examiner Signa	ture Luca St	Date consists.	2/16/04
	July 3		

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3). A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).